Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies (Q34609717)

3 August 2017

0 references

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies (English)

1 reference

3 August 2017

1 reference

1 reference

Katherine L O'Brien

0 references

Shabir A Madhi

1 reference

3 August 2017

Mathuram Santosham

1 reference

3 August 2017

Keith P Klugman

1 reference

3 August 2017

Sherryl Baker

1 reference

3 August 2017

Robert Kohberger

1 reference

3 August 2017

George R Siber

1 reference

3 August 2017

Ih Chang

series ordinal

1 reference

3 August 2017

Philip Fernsten

series ordinal

1 reference

3 August 2017

Peter Paradiso

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

21 February 2007

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

3816-3826

1 reference

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Immunogenic protein contaminants in pneumococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Periodate oxidation of R36A pneumococci greatly enhances production of hybridomas secreting anti-protein antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.01.119

10.1016/J.VACCINE.2007.01.119

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference